Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
Oct 13, 2015
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced the completion of enrollment in the ORBIT-3 trial, the second
Aradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29
Sep 23, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced that Chief Financial Officer, Nancy Pecota , will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015 , at 3:00 p.m. ET .
Aradigm Corporation Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
Sep 22, 2015
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced the completion of enrollment in the ORBIT-4 Phase III pivotal
Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin to Be Presented at ICAAC/ICC 2015
Sep 10, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (NASDAQ:ARDM) (the "Company") demonstrated that Aradigm's investigational drugs, Lipoquin® and Pulmaquin®, significantly reduced pulmonary non-tuberculous mycobacteria infection
Aradigm Announces Second Quarter 2015 Financial Results
Aug 13, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2015 . Total revenue was $10.0 million for the second quarter of 2015, compared with $12.2 million in revenue for the second
Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2015 International Conference
May 12, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Scientists from the Oregon State University , Corvallis (OSU) and Aradigm Corporation (NASDAQ: ARDM) (the "Company") demonstrated that Aradigm's investigational drugs Lipoquin® and Pulmaquin® significantly reduced the growth of the pulmonary non-tuberculous
Aradigm Announces First Quarter 2015 Financial Results
May 11, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2015 . Total revenue was $8.8 million for the first quarter of 2015, compared with $6.6 million in revenue for the first
Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry, Manufacturing and Controls) and Quality
Apr 21, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) ("Aradigm" or the "Company") today announced that Robert A. Reed , PhD has been appointed as Aradigm's Vice President, Regulatory (CMC) and Quality, reporting to Igor Gonda , President and Chief Executive Officer. Dr.
Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City
Apr 16, 2015
Event Will Feature a Presentation by KOL David Griffith, MD HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) ("Aradigm" or the "Company") announced today that it will host a Key Opinion Leader Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (non-CF BE) on Thursday,
Aradigm Announces Fourth Quarter 2014 and Full Year Financial Results
Mar 17, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2014 . Fourth Quarter 2014 Results The Company recorded $8.1 million in revenue in the fourth quarter of 2014 compared with
Aradigm Corporation President & CEO Dr. Igor Gonda, Ph.D. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live"
Feb 27, 2015
Live Interview to Air on February 28th, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2015 on February 10
Feb 04, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 17 th Annual BIO CEO & Investor Conference 2015 on Tuesday, February 10, 2015 , at 2:30 p.m. ET .
Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia
Jan 14, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that the European Patent Office has issued an important new composition of matter patent entitled "Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile,"
Aradigm to Present at Biotech Showcase 2015 on January 14
Jan 08, 2015
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present an overview of the Company at Biotech Showcase 2015 on Wednesday, January 14, 2015 , at 2:30 p.m. Pacific time .
Aradigm to Present at the Stifel Healthcare Conference 2014
Nov 12, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that Igor Gonda , Aradigm's President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference 2014 at the New York Palace Hotel in New York, New
Aradigm Announces Third Quarter 2014 Financial Results
Nov 07, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2014 . Total revenue was approximately $6.6 million for the third quarter of 2014 compared with revenue of approximately
FDA Grants Fast Track Designation to Aradigm's Pulmaquin for Non-Cystic Fibrosis Bronchiectasis
Sep 04, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, Pulmaquin®, for treatment of non-cystic fibrosis bronchiectasis (non-CF BE)
Aradigm Announces Second Quarter 2014 Financial Results
Aug 07, 2014
NASDAQ listing achieved upon completion of reverse split HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2014 . Total revenue was $12.2 million for the second quarter of
Aradigm to Host Analyst Meeting and Webcast on August 12 in New York City
Aug 06, 2014
Event Will Feature Presentations by KOLs Diana Bilton, MD, and Byron Thomashow , MD HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") announced today that it will host an Analyst Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (non-CF BE) on Tuesday,
Aradigm to Host Corporate Update Conference Call on June 26
Jun 25, 2014
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") will host a corporate update conference call at 8:00 am ET ( 5:00 am PT ) on Thursday, June 26, 2014 . The Company will review recent significant milestones, as well as progress with the Pulmaquin® program in
Displaying 41 - 60 of 234
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.